Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma

Cancer

Volumn 85, Issue 12, 1999, Pages 2570-2576

  Ohta, Yasuhiko ^a,b   Shridhar, Viji ^a   Kalemkerian, Gregory P ^a   Bright, Robert K ^a   Watanabe, Yoh ^b   Pass, Harvey I ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Malignant mesothelioma; Methylation; Thrombospondin 1 (TSP 1); Vascular endothelial growth factor (VEGF)

Indexed keywords

MESSENGER RNA; THROMBOSPONDIN 1; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; METHYLATION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SEQUENCE; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; LYMPHOKINES; MALE; MESOTHELIOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; THROMBOSPONDIN 1; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033564827     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990615)85:12<2570::AID-CNCR12>3.0.CO;2-F     Document Type: Article

References (24)

1. Varani J, Rister BL, Hughes LA, Carey TE, Fligiel SEG, Dixit VM. Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells. Clin Exp Metastasis 1989;7:265-76.
2. Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V. Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991;87:1883-8.
3. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994;124:183-93.
4. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J Cell Biol 1995; 130:503-6.
5. Gao AG, Lindberg FP, Dimitry JM, Brown EJ, Frazier WA. Thrombospondin modulates alpha V beta 3 function through integrin associated protein. J Cell Biol 1996;135: 533-44.
6. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP. CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 1997;138: 707-17.
7. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
8. Roth JJ, Reiver DM, Granick MS, Rothman VL, Nicosia RF, Tuszynski GP. Histopathology and clinical assessment correlate with the cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) receptor of thrombospondin-1 in breast tumors. Histol Histopathol 1997;12:1013-8.
9. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045-9.
10. Mattern J, Koomagi R, Volm M. Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas. Int J Oncol 1995;6:1059-62.
11. Ohta Y, Endo Y, Tanaka M, Simizu J, Oda M, Hayashi Y, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-6.
12. Rusch VW. A proposed new International TNM Staging System for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 1996;14: 1-12.
13. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, et al. The human gene for vascular endothelial growth factor. J Biol Chem 1991;266:11947-54.
14. Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997;57:3370-4.
15. Shridhar V, Siegfried J, Hunt J, Alonso MM, Smith DI. Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res 1994;54:2084-7.
16. Mantel M, Haenzel W. Statistical aspects of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
18. Segal MR. Regression trees for censored data. Biometrics 1988;44:35-47.
19. Roberts DD, Sherwood JA, Ginsburg V. Platelet thrombospondin mediates attachment and spreading of human melanoma cells. J Cell Biol 1987;104:131-9.
20. Pratt DA, Miller WR, Dawes J. Thrombospondin in malignant and non-malignant breast tissue. Eur J Cancer Clin Oncol 1989;25:343-50.
21. Hermann JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MST1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995;55:4525-30.
22. Ottaviano YL, Issa J-PJ, Parl FF, Smith HS, Baylin SB, Davidson NE. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994;54:2552-5.
23. Issa J-PJ, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 1996;56:973-7.
24. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.